Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.57 is 98% above its 5-year average of -93.21, near the high end of its 5-year range (-280.77–-1.12).
70.18% above its 12-month average of -5.27.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.08.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 18 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.57
EARNINGS PER SHARE (EPS) AVG TTM
-5.27
EARNINGS PER SHARE (EPS) AVG 3Y
-99.59
EARNINGS PER SHARE (EPS) AVG 5Y
-93.21
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+70.18%
CURRENT VS 3Y AVG
+98.42%
CURRENT VS 5Y AVG
+98.32%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Canton Strategic Holdings Inc
Market Cap
$179.70M
Earnings Per Share (EPS)
-1.57
TTM Avg
-5.27
3Y Avg
-99.59
5Y Avg
-93.21
Market Cap
$176.96M
Earnings Per Share (EPS)
-27.00
TTM Avg
-15.00
3Y Avg
-27.00
5Y Avg
-32.85
Market Cap
$184.12M
Earnings Per Share (EPS)
-0.23
TTM Avg
-0.59
3Y Avg
-0.77
5Y Avg
-0.88
Market Cap
$174.17M
Earnings Per Share (EPS)
-2.80
TTM Avg
-1.25
3Y Avg
-14.14
5Y Avg
-22.50
Market Cap
$173.04M
Earnings Per Share (EPS)
-1.02
TTM Avg
-0.60
3Y Avg
-1.87
5Y Avg
-1.57
Market Cap
$172.99M
Earnings Per Share (EPS)
-0.41
TTM Avg
-0.39
3Y Avg
-0.36
5Y Avg
-0.55
Market Cap
$192.97M
Earnings Per Share (EPS)
-0.99
TTM Avg
-0.66
3Y Avg
-3.05
5Y Avg
-5.28
Market Cap
$162.82M
Earnings Per Share (EPS)
-1.13
TTM Avg
-2.24
3Y Avg
-2.81
5Y Avg
-2.43
Market Cap
$160.82M
Earnings Per Share (EPS)
-0.90
TTM Avg
-1.19
3Y Avg
-2.61
5Y Avg
-1.83
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Canton Strategic Holdings Inc (CNTN) | $179.70M | -1.57 | -5.27 | -99.59 | -93.21 |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | -27.00 | -15.00 | -27.00 | -32.85 |
| Journey Medical Corporation (DERM)vs › | $184.12M | -0.23 | -0.59 | -0.77 | -0.88 |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | -2.80 | -1.25 | -14.14 | -22.50 |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | -1.02 | -0.60 | -1.87 | -1.57 |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | -0.41 | -0.39 | -0.36 | -0.55 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | -0.99 | -0.66 | -3.05 | -5.28 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | -1.13 | -2.24 | -2.81 | -2.43 |
| Inogen, Inc. (INGN)vs › | $160.82M | -0.90 | -1.19 | -2.61 | -1.83 |
| AN2 Therapeutics, Inc. (ANTX)vs › | $202.05M | -1.07 | -1.44 | -2.10 | -1.78 |
Trailing EPS (TTM)
$-1.57
Forward EPS (Est.)
$-0.75
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.12 |
| 2024-12-31 | -9.41 |
| 2023-12-31 | -107.08 |
| 2022-12-31 | -280.77 |
| 2021-12-31 | -72.81 |
| 2020-12-31 | -88.05 |
| 2019-12-31 | -55.56 |
